Cost of oral care · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
BMD: % change in BMD at the lumbar spine · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in volumetric BMD of distal radius or tibia · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in fracture frequency · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Number of participants reporting an adverse event · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in NTX (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Change in BAP (assessed 4 to 6 months post‐intervention) · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Receipt of intravenous treatment for hypoglycaemia (yes/no) · newborn infants with hypoglycaemia
It is very uncertain whether oral dextrose gel changes receipt of intravenous treatment for hypoglycaemia before discharge… compared with control (very low certainty).
1 finding from 1 review
Rate of intravenous rehydration during ED stay · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) probably leads to lower rate of intravenous rehydration during ED stay compared with placebo (moderate certainty).
1 finding from 1 review
Rate of intravenous rehydration up to 72 hrs following discharge from ED (best ‐ worst scenario) · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) may leads to lower rate of intravenous rehydration up to 72 hrs following discharge… compared with placebo (low certainty).
1 finding from 1 review
Rate of intravenous rehydration up to 72 hrs following discharge from ED (worst ‐ best scenario) · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) may leads to lower rate of intravenous rehydration up to 72 hrs following discharge… compared with placebo (low certainty).
1 finding from 1 review
Disease-free survival · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral showed no clear difference in disease‐free survival compared with intravenous fluoropyrimidines (moderate certainty).
1 finding from 1 review
Grade ≥ 3 neutropenia/granulocytopenia · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral may leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (low certainty).
1 finding from 1 review
Overall survival · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).
1 finding from 1 review
Grade ≥ 3 diarrhoea · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
It is very uncertain whether oral changes grade ≥ 3 diarrhoea compared with intravenous fluoropyrimidines (very low certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral may leads to higher grade ≥ 3 hand foot syndrome compared with intravenous fluoropyrimidines (low certainty).
1 finding from 1 review
Grade ≥ 3 neutropenia/granulocytopenia · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral probably leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (moderate certainty).
1 finding from 1 review
Progression‐free survival · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral probably leads to higher progression‐free survival compared with intravenous fluoropyrimidines (moderate certainty).
1 finding from 1 review
Overall survival · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).
1 finding from 1 review
Grade ≥ 3 diarrhoea · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral may leads to higher grade ≥ 3 diarrhoea compared with intravenous fluoropyrimidines (low certainty).
1 finding from 1 review